Latest Breaking News On - ஐயா ஆண்ட்ரூ அறிவாற்ற்ல் - Page 1 : comparemela.com
Activist investor Elliott tries to force GSK boss to reapply for her job
theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.
Leading Responsibly In A World Moving Through Crisis
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Hospitality firms urgently need clarity from Sunak about £2 5bn of unpaid rent
theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.
Her comments came as the firm reported its first-quarter results just days after Elliott, whose co-chief executive is Paul Singer, which is notorious for its aggressive tactics, emerged as a major shareholder.
That has put Walmsley’s broader strategy as chief executive under the microscope. Analysts believe Elliott could push for cuts to research spending, a speedier separation of the consumer arm, a spin-off of the vaccines division or even her removal.
It was claimed by one top 20 shareholder that Walmsley, whose background is in consumer businesses, has ruffled feathers by opting to lead the remaining pharmaceuticals and vaccine company when the consumer arm is broken off.
GlaxoSmithKline may not be doing so well compared to peers, City says
Chief executive Emma Walmsley expressed firm commitment to her plans after the spinoff on Wednesday, which may leave Elliott Management little leeway with its agenda
GlaxoSmithKline PLC’s (LON:GSK) pipeline value relative to peers may be weak and its research and development productivity may be poor, City analysts say.
The pharma giant scores below average when compared to peers with poor growth and replacement power product concentration, offsetting good pricing power and limited risk around generics, Credit Suisse noted.
On Wednesday, the company said healthcare systems and consumer trends will approach normality in the second half of the year.